Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Late-Stage Pipeline

50%

3 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

5 recruiting

Enrollment Performance

Analytics

Phase 3

3(50.0%)

Phase 2

2(33.3%)

Phase 1

1(16.7%)

6Total

Phase 3(3)

Phase 2(2)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT07490262Phase 2Recruiting

A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.

Role: lead

NCT06945107Phase 3Active Not Recruiting

A Study of Switching to Picankibart in Chinese Patients With Plaque Psoriasis With an Inadequate Response to Interleukin-17 Monoclonal Antibody Therapy

Role: lead

NCT07295509Phase 2Recruiting

A Study of Picankibart in Patients With Active Psoriatic Arthritis

Role: lead

NCT07377643Phase 3Recruiting

IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer

Role: lead

NCT07265284Phase 3Recruiting

A Study to Evaluate Efficacy and Safety of IBI112 in Adolescent Participants With Moderate to Severe Plaque Psoriasis

Role: lead

NCT06963281Phase 1Recruiting

Study of IBI3020 Treatment in Participants With Late-Stage Solid Tumors

Role: lead

All 6 trials loaded